Clinical Trial Update: Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy) [Phase 3]

View source ↗

Summary

Phase 3 study ClarIDHy evaluating ivosidenib in IDH1-mutated advanced cholangiocarcinoma has completed enrollment with results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma

Drugs mentioned

• Tibsovo (ivosidenib)

Snippet

Sponsor: Institut de Recherches Internationales Servier | Conditions: Advanced Cholangiocarcinoma, Metastatic Cholangiocarcinoma | Phase 3 | Status: COMPLETED | Results posted: 2022-04-13